Knoll Pharma: A strong dose - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Knoll Pharma: A strong dose

Jul 29, 2000

A 30% growth in earnings on a 13.6% growth in the topline is a strong enough dose but Knoll has during the quarter also sold units of mutual funds which have realised an extraordinary profit of Rs 160.5 m.

(Rs m) 2QFY99 2QFY00 Change
Sales 790 897 13.6%
Other Income 18 30 64.5%
Expenditure 688 763 10.9%
Operating Profit (EBDIT) 102 134 31.4%
Operating Profit Margin (%) 12.9% 14.9%  
Interest 1 7  
Depreciation 14 14 6.7%
Profit before Tax 106 143 35.2%
Other Adjustments   161  
Tax 20 30  
Profit after Tax/(Loss) 86 273 217.5%
Net profit margin (%) 10.9% 12.6%  
No. of Shares (m) (eoy) 16.2 16.2  
Diluted no. of shares (m) 16.2 16.2  
Diluted Earnings per share* 21.3 67.5  
*(annualised)      

The company is a leading player in the anti–diabetes, pain control and antacid market with brands such as Brufen, Digene, Epilex (anti–epilepsy) and Cremmafin (laxative) market.

During the quarter the company has entered into an agreement with Kalpataru Homes for the part development of its Sion premises for a consideration of Rs 140 m.

The stock quotes at a price of Rs 314 (near its 52 week low of Rs 300) which implies an earning multiple of 4.6 times the second quarter annualised earnings.


Equitymaster requests your view! Post a comment on "Knoll Pharma: A strong dose". Click here!

  

More Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 24, 2020 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS